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Abstract
Background: Alzheimer’s disease (AD)-linked protein, presenilin 1 (PS1), is present at the synapse, and the
knock-out of presenilin in mice leads to synaptic dysfunction. On the other hand, synaptic activity was shown
to influence PS1-dependent generation of distinct amyloid β (Aβ) species. However, the precise nature of
these regulations remains unclear. The current study reveals novel role of PS1 at the synapse, and deciphers
how PS1 and synaptic vesicle-associated protein, synaptotagmin 1 (Syt1) modulate each other functions in
neurons via direct activity-triggered interaction. Additionally, the therapeutic potential of fostering PS1-Syt1
binding is investigated as a synapse-specific strategy for AD prevention.
Methods: PS1-based cell-permeable peptide targeting PS1-Syt1 binding site was designed to inhibit PS1-Syt1 interaction
in neurons. PS1 conformation, synaptic vesicle exocytosis and trafficking were assayed by fluorescence lifetime imaging
microscopy (FLIM), glutamate release/synaptopHluorin assay, and fluorescence recovery after photobleaching, respectively.
Syt1 level and interaction with PS1 in control and sporadic AD brains were determined by immunohistochemistry and
FLIM. AAV-mediated delivery of Syt1 into mouse hippocampi was used to investigate the therapeutic potential of
strengthening PS1-Syt1 binding in vivo. Statistical significance was determined using two-tailed unpaired Student’s t-test,
Mann-Whitney’s U-test or two-way ANOVA followed by a Bonferroni’s post-test.
Results: We demonstrate that targeted inhibition of the PS1-Syt1 binding in neurons, without changing the proteins’
expression level, triggers “pathogenic” conformational shift of PS1, and consequent increase in the Aβ42/40 ratio.
Moreover, our data indicate that PS1, by binding directly to Syt1, regulates synaptic vesicle trafficking and facilitates
exocytosis and neurotransmitter release. Analysis of human brain tissue revealed that not only Syt1 levels but also
interactions between remaining Syt1 and PS1 are diminished in sporadic AD. On the other hand, overexpression of
Syt1 in mouse hippocampi was found to potentiate PS1-Syt1 binding and promote “protective” PS1 conformation.
Conclusions: The study reports novel functions of PS1 and Syt1 at the synapse, and demonstrates the importance of
PS1-Syt1 binding for exocytosis and safeguarding PS1 conformation. It suggests that reduction in the Syt1 level and
PS1-Syt1 interactions in AD brain may present molecular underpinning of the pathogenic PS1 conformation, increased
Aβ42/40 ratio, and impaired exocytosis.
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Background
Aberrant amyloid β (Aβ) generation resulting in increased
Aβ42/total ratio, and loss of cortical and hippocampal
synapses have been established as important contributors
to Alzheimer’s disease (AD) pathophysiology [1–8]. How-
ever, amyloid deposition and reduced levels of synaptic
proteins found in postmortem human brain tissue do not
reveal the early stage molecular events preceding the
observed pathology, and do not allow to determine
dynamic functional relationship between the synaptic im-
pairments and Aβ generating machinery.
The amyloid precursor protein (APP) and its proces-
sing enzymes, β-secretase 1 (BACE1) and presenilin 1
(PS1)/γ-secretase, are abundantly present at the synaptic
terminals [9–12], enabling local production of Aβ. The
generation of the longer Aβ42/43 species readily forming
toxic oligomers is influenced by the PS1/γ-secretase con-
formational state [13–20]. Fluorescence lifetime imaging
microscopy (FLIM) and real-time Förster resonance
energy transfer (FRET) assays of the PS1 domain
arrangement demonstrated that PS1 exists in a dynamic
equilibrium of conformational states. Although the
assays do not address the detailed structural rearrange-
ments within the PS1 molecule, they can reliably
distinguish between the normal, so-called “open” and
pathogenic, named “closed” PS1 conformations. These
are characterized by greater and smaller distance,
respectively, between the fluorophores labeling different
PS1 domains. “Open” and “closed” PS1 conformations
correspond to lower and higher ratio of the Aβ42 to
Aβ40 peptides, respectively [12, 15, 21, 22]. However,
the precise molecular mechanisms altering the arrange-
ment of the PS1 domains in neurons remain unknown.
Although the role of PS1 in Aβ generation has re-
ceived the greatest attention, presenilin knockout studies
have suggested that PS1 may also be involved in neuro-
transmission [23, 24]. However, the exact role of the
“undisturbed” PS1, expressed at the physiological level,
and the specific molecular mechanism of its involvement
in synaptic vesicle release remain unexplored.
It has recently been reported that both APP [25, 26]
and PS1 interact with the pre-synaptic protein synapto-
tagmin 1 (Syt1) [12], a calcium sensor in synaptic vesicle
exocytosis and neurotransmitter release [27–29]. More-
over, knock-down of Syt1 in PC12 cell line was found to
alter APP processing and reduce Aβ generation [12, 25].
However, Syt1 knock-down also impaired subcellular
compartmentalization of PS1 and BACE1, resulting in
decreased maturation and stability of BACE1, and
diminished γ-secretase activity [12, 25]. Therefore, the
significance of the direct PS1-Syt1 binding per se, as well
as functional outcomes of the disrupted PS1-Syt1 inter-
action for synaptic physiology and/or their relevance to
AD pathology remain unknown.
In the current study we investigate in detail the func-
tional interplay between PS1 and Syt1 by selectively
targeting the PS1-Syt1 binding using PS1-based cell-
permeable peptide corresponding to the PS1-Syt1 inter-
action site, without altering the proteins’ expression level.
Using complementary cell/molecular biology approaches
and functional assays, we present evidence that calcium
influx-induced binding between PS1 and Syt1 is essential
for regulation of the synaptic vesicle trafficking along
neuronal processes, promotion of exocytosis and neuro-
transmitter release. Moreover, we provide direct evidence
that Syt1 binding to PS1 is important for maintenance of
the protective PS1 conformation in neurons, and for
determination of the local, synaptic pool of Aβ species.
Finally, we demonstrate that not only Syt1 levels but also
proximity between the remaining Syt1 and PS1 is de-
creased in sporadic AD brain, and that overexpression of
Syt1 in vivo has potential to promote PS1-Syt1 interaction,
and to stabilize the protective, “open” PS1 conformation.
Methods
Human brain tissue
The medial temporal cortex of the sporadic Alzheimer’s
disease (sAD) patients (92.25 ± 4.52 years old) with
neuropathologically confirmed Braak V-VI stage, and
age- (90.75 ± 1.60 years old) and post mortem
interval-matched control tissue was obtained from the
Massachusetts Alzheimer’s Disease Research Center
Brain Bank. For the immunohistochemical analysis,
medial temporal lobe specimens were fixed for 48 h
with 4% paraformaldehyde (PFA) and cut into 50 μm
coronal sections using a sliding freezing microtome
(Leica SM 2000R, Bannockburn, IL).
Animal research
Syt1-V5 expression in vivo in hippocampi of wild type male
C57BL/6 mice was achieved using stereotaxic injection
(stereotaxic coordinates from bregma: 3.1 mm posterior;
2.8 mm lateral and 2.5 mm depth from brain surface) of
adeno-associated viruses serotype 2/8 (AAV2/8) carrying
hSyn. Syt1-V5 or control, empty, expression plasmids. One
month after the AAV2/8 injection, the mice were sacrificed.
The mice were euthanized using CO2 asphyxiation and
perfused intracardially with phosphate-buffered saline
(PBS). The brains were dissected, fixed by immersion in
4% PFA, 15% glycerol (Sigma-Aldrich, Saint Louis, MO)
in PBS and cryoprotected using 30% glycerol in PBS. Prior
to immunostaining, the brains were cut on freezing sliding
microtome (Leica SM 2000R, Bannockburn, IL) into 35
μm-thick coronal sections.
Cell culture
Rat pheochromacytoma cell line (PC12) was a kind gift
from Dr. Amy B. Harkins (St. Louis University School of
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Medicine, St. Louis, MO) [30]. The PC12 cells were cul-
tured in RPMI Medium 1640 supplemented with 10%
heat-inactivated horse serum, 5% fetal bovine serum
(FBS) (ThermoScientific, Waltham, MA) in a 37 °C, 5%
CO2 incubator. Transfections were performed using
lipofectamine 3000 (ThermoScientific, Waltham, MA)
according manufacturer’s protocol.
Mouse embryonic fibroblasts (MEF) with PSEN1
and PSEN2 knock-out (PS DKO) and MEF PS DKO
stably expressing PS1 wt or PS1 Δe9 were kind gifts
from Dr. Bart De Strooper [31]. The cells were maintained
in OptiMEM supplemented with 5% fetal bovine serum
(FBS) (ThermoScientific, Waltham, MA) in a 37 °C, 5%
CO2 incubator. Transfections were performed using
lipofectamine LTX with Plus reagent (ThermoScientific,
Waltham, MA) according manufacturer’s protocol.
Mixed cortical primary neurons from 16 to 18 embryonic-
day-old embryos were enzymatically dissociated using
papain dissociation system (Worthington Biochemical
Corporation, Lakewood, NJ). The neuronal cultures were
maintained in Neurobasal medium supplemented with 2%
B27 supplement, 1% GlutaMax, and 1% penicilin/
streptomycin mix (ThermoScientific, Waltham, MA) in a
37 °C, 5% CO2 incubator. The neurons were transfected
using lipofectamine 2000 (ThermoScientific, Waltham,
MA) following the supplier’s protocol.
Chemicals and treatments
Calcium influx was induced by 15-min application of
50 mM KCl (Sigma-Aldrich, Saint Louis, MO) for neu-
rons and PC12 cell line, or of 5 μM A23187 calcium iono-
phore (Sigma-Aldrich, Saint Louis, MO) for MEFs.
PS1-Syt1 interactions were blocked by incubating pri-
mary neurons for 2 h at 37 °C with 5 μM of cell-permeable
peptide (CPP), we named PS1-LNT. The PS1-LNT was
obtained by fusing 47–57 amino acids (aa) from HIV1
TAT protein (YGRKKRRQRRR) with the N-terminal por-
tion of the cytosolic PS1 loop domain through a GGG
linker. A peptide comprising 47–57 aa from HIV1 TAT
fused to a scramble sequence ENSFRFLADIFPAKAFPV
RFE through a GGG linker was used as a negative control.
The peptides were synthesized at the MGH peptide/
protein core facility https://researchcores.partners.org/pep-
cor/about.
Expression plasmids
Human wild type (wt) presenilin 1 (PS1) was cloned into
pcDNA™3.1. (+) (ThermoScientific, Waltham, MA). The
PS1 sequence was tagged with an N-terminal FLAG and
His tags to facilitate detection of exogenous versus
endogenous PS1.
The His-FLAG-huPS1 construct (PS1 del265-279) was
created by introducing 15 aa deletion within the huPS1 se-
quence using a QuickChange site-directed mutagenesis
kit (Stratagene, La Jolla, CA) according to the manufac-
turer’s recommendation.
Human wt synaptotagmin 1 (Syt1) was cloned into
pcDNA™ 6 V5 Myc expression vector (ThermoScientific,
Waltham, MA).
Plasmids encoding vesicular glutamate transporter 1
(vGlut1) fused with pH-sensitive GFP (synaptophluorin
(SypHy)), eGFP-tagged synaptophysin (eGFP-Syp) and
eGFP-tagged tubulin (eGFP-Tub) were kind gifts from
Dr Pamela McLean (Mayo Clinic, Jacksonville, FL).
Cytotoxicity assay
Cytotoxicity was analyzed using lactate dehydrogenase
(LDH) cytotoxicity assay (Roche, Indianapolis, IN).
Briefly, conditioned medium was collected from the re-
spective wells, mixed with the assay solution, incubated
for 20 min in the dark, and the absorbance at 490 nm
was measured using a spectrophotometer. For a positive
control, cells were incubated for 45 min at 37 °C with
1% Triton X (TX)-100.
ELISA for Aβ40 and Aβ42
Intracellular or secreted level of Aβ was quantified using
human/rat Aβ40 and Aβ42 (high-sensitive) enzyme-
linked immunosorbent assay (ELISA) kits (Wako, Japan)
according to the manufacturer’s protocol. The Aβ
levels detected in the conditioned medium or cell ly-
sates (determined in [pmol]), were normalized to the
total amount of protein extracted from the respective
cells (quantified in [g]) using BCA protein assay
(Pierce, Rockford, IL).
Glutamate release assay
Glutamate release was stimulated by application of 50
mM KCl in Hank’s balanced salt solution after 2-h pre-
treatment with scramble or PS1-LNT peptides. The
glutamate uptake was inhibited by the addition of DL-
threo-β-benzyloxyaspartate (DL-TBOA), an excitatory
amino acid transporters 1 and 2 (EAAT1, EAAT2) inhi-
bitor [32]. The level of glutamate in the conditioned
medium was determined using Amplex Glutamate assay
(ThermoScientific, Waltham, MA) according to the man-
ufacturer’s protocol. Overnight pre-treatment with 37 nM
tetanus toxin (TeTx) was used as a control.
NanoOrange protein quantitation
The total amount of protein in the conditioned medium
collected from neurons pre-treated for 2 h with scramble
or PS1-LNT peptides, and stimulated for 15 min with
50 mM KCl was determined using NanoOrange protein
quantitation assay (ThermoScientific, Waltham, MA),
according the manufacturer’s protocol. Briefly, the serum-
free conditioned medium was diluted 100 times in
NanoOrange reagent, and the mixtures were heated at
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95 °C for 10 min protected from light. The samples were
cooled down to room temperature, and the fluorescence,
corresponding to the total amount of protein in the sam-
ples, was measured using Wallac Victor 2 plate reader
(PerkinElmer, Waltham, MA) with filters and settings
allowing excitation at 485 nm and capturing the emission
at 590 nm. Standard curve was generated by serial dilution
of the bovine serum albumin (BSA) in the NanoOrange
reagent.
Exocytosis assay
The exocytosis was monitored using a previously estab-
lished protocol [33, 34]. Briefly, the primary neurons were
transfected with a construct encoding a pH-sensitive
reporter of synaptic vesicle exocytosis, synaptophluorin
(SypHy). The acidic pH of the synaptic vesicles results in
quenching of the SypHy fluorescence. During the exocyt-
osis event the pH-sensor is exposed to the extracellular
neutral pH, which results in the dequenching of the
SypHy signal. The SypHy was excited using 488 nm Argon
laser at low power, 4–6% to reduce photobleaching and
phototoxicity, and the fluorescence was monitored at 63x
magnification using time-lapse recording with 3 s interval
on Zeiss 510 Meta laser scanning confocal microscope
equipped with ZEN 2009 software. First, five frames were
collected before the stimulus to determine the baseline
SypHy fluorescence in cells pre-treated for 2 h with the
scramble or PS1-LNT peptides at 5 μM concentration.
Then exocytosis was triggered by 50 mM KCl stimulation,
and the subsequent frames were acquired immediately
following the KCl application. The laser intensity and
photomultiplier parameters (PMIs) were adjusted to avoid
saturation of the signal on both pre- and post-stimulus
images. The fluorescence intensity of the SypHy pre- and
post-stimulus was analyzed using ImageJ 1.46c software.
The region of interests (ROIs) were selected around the
spatially resolved SypHy-positive puncta corresponding to
synaptic terminals.
Fluorescence recovery after photobleaching (FRAP)
The 12-14 DIV neurons were transfected with plasmids
encoding eGFP-synaptophysin (eGFP-Syp) as a fluorescent
reporter of synaptic vesicles or eGFP-tubulin (eGFP-Tub)
as a control. For the imaging the culture medium was
substituted with Hank’s balanced salt solution (HBSS)
(ThermoScientific, Waltham, MA), and the cell culture
dishes were placed on an imaging stage in the microscope
environmental chamber (37 °C, 5% CO2). The eGFP was
excited using 488 nm Argon laser at low power (2–4%) to
avoid photobleaching during the time-lapse imaging; the
emitted light was passed through a band pass emission
filter. Five pre-bleach images at 63x magnification with 2x
zoom were recorded to determine the baseline fluores-
cence intensity of the target protein. Then, the eGFP-Syp
or eGFP-Tub fluorescence was photobleached within the
selected ROIs using 75 iterations with 100% 488 nm
Argon laser, and the imaging was continued for 90 s using
time-lapse recording with 1-s intervals. Three ROIs were
recorded and analyzed: bleached, control (not bleached),
and background. The fluorescence intensities of the
selected ROIs were measured using ImageJ 1.46c software.
The recorded data were analyzed with Microsoft Excel
2007 and GraphPad Prism 5 software. Following the
background subtraction, the intensity of the bleached
ROI was normalized to its initial pre-bleach intensity
(calculated as an average of the 5 pre-bleach frames) and
to the intensity of the control, not bleached region. Then
the data were further normalized in respect to the inten-
sities immediately after bleaching (value = 0, full scale
normalization). In order to determine the statistical dif-
ference between the conditions, the mean fluorescence
recovery 10 s post-bleach was compared using unpaired
Student’s t-test.
Analysis of the spine density and spine morphology
Mouse primary neurons at 12–14 DIV were transfected
with pcDNA-eGFP. Two days post-transfection the neu-
rons were pre-treated for 2 h with scramble or PS1-LNT
peptides and depolarized for 15 min with 50 mM KCl.
The spine density and morphology were examined using
the LSM 510 Zeiss confocal microscope equipped with
the 488 nm excitation laser. The images were captured at
63x magnification, and consisted of a z-stack of pictures
taken at 0.5 μm intervals, and then projected into one
image. The images were analyzed using NeuronStudio
software [35]. The spine density was calculated by dividing
the number of spines by the length of the corresponding
neurite. In addition, the spines were categorized into three
morphological classes: mushroom, stubby and thin using
an algorithm implemented in the NeuronStudio applica-
tion. 30 neurites per condition from eight independent
experiments were analyzed.
Immunoprecipitation (IP)
Cells were lysed in 1% 3-[(3-cholamidopropyl) dimethy-
lammonio]-2-hydroxy-1-propanesulfonate (CHAPS) buf-
fer (50 mM HEPES, 100 mM NaCl, pH 7.4 and 1%
CHAPS) supplemented with HALT protease and phosphat-
ase inhibitor cocktails (ThermoScientific, Waltham, MA)
by pipetting up-and-down, passing through a 37-gauge
needle and rotating for 1 h at 4 °C. The lysates were centri-
fuged at 14,000xg for 15 min and the supernatants were
collected for the IP. Total protein in the samples was
measured using ThermoScientific Pierce BCA Protein
Assay (ThermoScientific, Waltham, MA). The aliquots of
the supernatant containing equal protein amount were in-
cubated with 3 μg of the respective antibody or normal
IgG, as a negative control, with end-over-end rotation over
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night at 4 °C. Subsequently, 30 μl of Protein G Dynabeads
(ThermoScientific, Waltham, MA) were added to the sam-
ples and incubated with end-over-end rotation for 10 min
at room temperature. The beads were collected using a
magnetic tube rack, washed twice with the 1% CHAPS buf-
fer and once with the wash buffer containing 50 mM
HEPES, 100 mM NaCl, pH7.4. The protein was eluted by
5-min boiling in 25 μl 2x LDS, 1x reducing agent buffer
(ThermoScientific, Waltham, MA).
Immobilized metal affinity chromatography (IMAC)
IMAC technique was used to pull down His-PS1 and en-
dogenous Syt1 complexes from PC12 cells transfected
with His-tagged PS1 wt or PS1 del265-279. Briefly, 24 h
following the transfection the cells were stimulated for
15 min with 50 mM KCl, harvested and lysed in a buffer
containing 50 mM HEPES, 100 mM NaCl, protease in-
hibitors (Roche, Indianapolis, Indiana) and 1% CHAPS.
The lysates were incubated for 1 h at 4 °C and centri-
fuged at 14,000xg for 15 min to collect the soluble frac-
tions. Protein concentration in each sample was
determined using a BCA assay (ThermoScientific,
Waltham, MA) according the manufacturer’s recom-
mendations. The samples with equal amount of protein
were supplemented with 20 mM imidazole to reduce
non-specific binding, and were incubated for 2 min with
30 μl MagneHis Ni-Particles (Promega, Madison, WI).
Following the incubation, the beads were washed 3 times
with the lysis buffer, and the protein was eluted with the
elution buffer provided with the MagneHis Ni-Particles,
containing 500 mM imidazole.
In vitro PS1-Syt1 binding assay
Syt1 tagged with V5 and His was overexpressed in PS
DKO MEF cells. The protein was extracted from the
cells using a lysis buffer containing 50 mM HEPES,
100 mM NaCl, protease inhibitors (Roche, Indianapolis,
Indiana) and 1% TX-100, and was immobilized on the
MagneHis Ni-Particles (Promega, Madison, WI) by 2-min
incubation in the presence of 20 mM imidazole to reduce
non-specific binding. Subsequently, 30 μl of the Syt1-V5-
His bound beads were added to the mouse brain lysates
containing 2 mg of total protein and prepared in a buffer
containing 50 mM HEPES, 100 mM NaCl, protease inhib-
itors (Roche, Indianapolis, Indiana), 1% CHAPS, 20 mM
imidazole, 2 mM CaCl2. 100 μg of PS1-LNT or scramble,
as a negative control, peptides were added to the samples.
Additional negative controls included Syt1-V5-His bound
beads incubated with the lysis buffer only, or empty beads
incubated with the mouse brain lysates. The mixtures
were incubated overnight at 4 °C with end-over-end rota-
tion. Then, the beads were washed 3 times with the 1%
CHAPS-based lysis buffer, and the attached protein was
eluted with the elution buffer provided with the MagneHis
Ni-Particles, containing 500 mM imidazole.
Western blotting
The proteins were resolved by electrophoresis on 4–12%
Bis-Tris NuPage polyacrylamide gels (ThermoScientific,
Waltham, MA) and transferred to nitrocellulose mem-
branes (GE Healthcare Lifesciences, Pittsburgh, PA)
using the BioRad system. Proteins were detected by im-
munoblotting with specific primary and corresponding
IRdye680/800- or HRP-conjugated secondary antibodies.
The membranes were developed using Odyssey Infrared
Imaging System (Li-COR, Lincoln, NE) or ECL Western
Blotting Substrate (Pierce, Rockford, IL), respectively.
The exposure times were adjusted to avoid signal satur-
ation. The relative amounts of the proteins were mea-
sured by densitometry using ImageStudio Lite Ver 5.2 or
ImageJ 1.46c software, respectively.
Immunocytochemistry (ICC) and immunohistochemistry
(IHC)
Cultured cells or brain tissue slices were fixed with 4%
PFA, permeabilized using 0.1% TX-100 or 0.4% TX-100,
respectively, and non-specific binding of the antibodies
was blocked by incubation with 1.5% normal donkey
serum (Jackson ImmunoResearch Labs, West Grove,
PA). The permeabilized and blocked samples were incu-
bated with primary antibodies overnight at 4 °C. Excess
antibodies were washed off and the samples were
incubated with corresponding Alexa Fluor 488- or Cy3-
conjugated secondary antibodies for 1 h at room
temperature. To visualize actin cytoskeleton, the cells
were incubated with fluorophore-conjugated phalloidin
(ThermoScientific, Waltham, MA) according to the
manufacturer’s protocol. The medium was supplemented
with 4′, 6-diamidino-2-phenylindole dihydrochloride
(DAPI) when visualization of nuclei was required. The
slides were mounted with VectaShield mounting
medium (Vector Laboratories, Inc., Burlingame, CA).
Antibodies
The following primary antibodies were used: anti-APP
CT (A8717, Sigma-Aldrich, St. Louis, MO); anti-β-
amyloid, 17–24 (clone 4G8) (800701, BioLegend, San
Diego, CA); anti-PS1 NT raised against the N terminus
of PS1 (APS11) (ab15456, Abcam, Cambridge, MA);
anti-PS1 CT raised against the C-terminus of PS1
(mAb5643, Cell Signaling Technology, Danvers, MA);
anti-PS1 loop raised against the loop domain between
transmembrane domains 6 and 7 of PS1 (E2000Y)
(ab76083, Abcam, Cambridge, MA); anti-Syt1 (AB5600,
Millipore, Temecula, CA); anti-Gapdh (mAb2118, Cell
Signaling Technology, Danvers, MA); anti-MAP2
(ab5392, Abcam, Cambridge, MA); anti-His (ab18184,
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Abcam, Cambridge, MA); anti-V5 (ab9116, Abcam,
Cambridge) and anti-FLAG M2 (F1804, Sigma-Aldrich,
St. Louis, MO). Alexa Fluor 488 (ThermoScientific,
Waltham, MA) and Cy3-labeled corresponding second-
ary antibodies (Jackson ImmunoResearch, West Grove,
PA) were used for confocal microscopy imaging, and
IRDye680/800- (Li-COR, Lincoln, NE) or HRP- (Jackson
ImmunoResearch, West Grove, PA) conjugated ones
were used for western blotting.
Fluorescent lifetime imaging microscopy (FLIM)
The proximity between PS1 and Syt1 or PS1 NT and
PS1 loop domain was evaluated by a previously vali-
dated Förster Resonance Energy Transfer (FRET)-based
fluorescence lifetime imaging microscopy (FLIM) assay
[22, 36, 37]. The samples were immunostained with the
following pairs of primary antibodies: a) anti-PS1 NT
(APS11) (ab15456, Abcam, Cambridge, MA) and anti-
Syt1 (AB5600, Millipore, Temecula, CA) or anti-FLAG
M2 (F1804, Sigma-Aldrich, St. Louis, MO) and anti-
Syt1 for analysis of PS1-Syt1 interaction; b) anti-PS1
NT (APS11) and anti-PS1 loop (EP2000Y) (ab76083,
Abcam, Cambridge, MA) for the analysis of PS1 con-
formation. Alexa Fluor 488 (AF488) and Cy3-labeled cor-
responding secondary antibodies were used as the donor
and acceptor fluorophores, respectively. AF488 donor
fluorophore was excited using pulsing Chameleon
Ti:Sapphire laser (Coherent Inc., Santa Clara, CA)
(two-photon excitation at 780 nm or 800 nm wave-
length, respectively). The baseline lifetime (t1) of the
AF488 donor fluorophore in the absence of the Cy3
acceptor was used as a negative control. The donor life-
times were determined using a high-speed photomultiplier
tube (MCP R3809; Hamamatsu, Bridgewater, NJ) and a
fast time-correlated single-photon counting acquisition
board (SPC-830; Becker & Hickl, Berlin, Germany). Bright
fluorophores were chosen, and prolonged image acquisi-
tion at low laser power was applied in order to acquire
sufficient number of photons for accurate curve fitting,
without photobleaching of the samples. The lack of photo-
bleaching was established by the lack of noticeable de-
crease in the count rate during acquisition time, and was
confirmed by analysis of the fluorescence intensity in pre-
and post-acquisition confocal images. Typically, 1,000–
5,000 photons per analyzed pixel (within the selected
intensity-thresholded region of interest (ROI)) were ac-
quired. If necessary, binning was applied to increase the
signal to noise ratio. The data were analyzed using
SPCImage software (Becker & Hickl, Berlin, Germany).
The analysis was performed on a cell-by-cell basis, and
the threshold was adjusted in order to exclude the low in-
tensity background fluorescence. The ROIs were selected
by outlining the neurons, and the average fluorescence
lifetimes per neuron were determined. Two analysis
modes were applied: two component analysis for cells in
vitro and mouse tissue and three component analysis for
human brain tissue to account for the presence of autofluo-
rescence, as described previously [38]. The lifetimes of the
“non-FRET” donor (t1), and if applicable of the autofluores-
cence (t3), were “fixed” and the remaining lifetime reflecting
the presence of FRET was calculated by the system as the
t2 value. This approach allows the exclusion of the “non-
FRETing” components, and thus reliable quantification of
the relative distances between the fluorophores, irrespec-
tively of their absolute amounts. Moreover, it significantly
improves the accuracy of the multicomponent analysis [39].
The fluorescence lifetime of the “non-FRETing” donor,
determined independently in every single experiment
was ~2.5 ns. Of note, the 4.1 ns has been reported for the
unconjugated Alexa Fluor 488 dye. However, conjugation
of the dye to the antibody results in the reduction in its
fluorescence lifetime [40]. To calculate %EFRET the follow-
ing equation was used: %EFRET = 100*(t1-t2)/t1.
The calculated lifetimes t2 were displayed on a 128×128
pixel matrix to create the pseudocoloured images where
green-to-red pixels represent shorter lifetimes, indicative
of short distance between the fluorophores, whereas blue
pixels correspond to longer lifetimes, indicative of a
greater distance between the donor and the acceptor. In
the images, the lifetimes were weighted by intensity, and a
threshold was adjusted to exclude dim pixels. Importantly,
all the analyses and the display parameters were kept con-
stant in each experiment, providing the most accurate
quantification of the acquired data.
Electron microscopy
Electron microscopy was applied to analyze the size and
distribution of the synaptic vesicles in mouse primary
neurons in vitro. The 12-14 DIV neuronal cultures were
fixed with ice-cold 2% PFA and 0.2% glutaraldehyde
(Sigma-Aldrich, St. Louis, MO) for 1 h at 4 °C. Then the
cells were washed three times with 0.1M phosphate
buffer pH 7.4 (PB), stained with 1% OsO4 in 0.1 M PB
for 1 h, dehydrated in graded ethanol series and flat-
embedded in EPON (Fluka). Ultrathin (50–60 nm thick)
sections were cut with an ultratome (LKB 8800,
Sweden), stained for 20 min with 5% uranyl acetate and
30 s in lead citrate, and examined using a JEM100-CX
transmission electron microscope (Japan). The images,
taken at magnifications of x19,000, were scanned with a
flatbed scanner at 600 dpi and 256 gray levels. Quantita-
tive image analysis was carried out using the ImageJ
1.46c software.
Statistics
Statistics were calculated with Microsoft Office Excel
2007. The graphs were prepared with GraphPad® Prism 5
(GraphPad Prism Software inc., La Jolla, CA). Gaussian
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distribution of the data was determined using
D’Agostino & Pearson omnibus normality test. The F sta-
tistics were calculated to determine the variance equality.
Subsequently, a standard two-tailed unpaired Student’s
t-test or Welch t-test was calculated for the normally dis-
tributed data and Mann-Whitney’s U-test for the data,
which did not meet the latter criterion. Glutamate release,
cytotoxicity and frequency distribution of synaptic vesicles
data were analyzed using two-way ANOVA followed by a
Bonferroni’s post-test. A p-value of <0.05 was considered
a predetermined threshold for statistical significance.
Results
Peptide corresponding to the N-terminal fragment of the
L6-7 domain of PS1 inhibits PS1-Syt1 interaction
Our previous data suggest that the interaction site
between presenilin 1 (PS1) and synaptotagmin 1 (Syt1) is
potentially located within the N-terminal part of the PS1
cytosolic loop domain between 6th and 7th transmembrane
helices (L6-7) [12]. First, to confirm that this region is in-
deed critical for the PS1-Syt1 binding, fifteen amino acid
deletion (del265-279) was introduced within the PS1
sequence (Fig. 1a). The construct was expressed in PC12
cells, and the proximity between PS1 and Syt1 was ana-
lyzed using antibody-based fluorescence lifetime imaging
microscopy (FLIM) assay in 15-min 50 mM KCl stimu-
lated cells. N-terminal PS1 FLAG-tag was used for PS1
detection to selectively visualize exogenous mutant PS1.
Reduced Förster resonance energy transfer (FRET)
efficiency indicates that the PS1 deletion mutant shows
reduced binding to Syt1, as compared to the wild type
(wt) PS1 (Fig. 1b and Additional file 1), supporting the im-
portance of the PS1 aa 265-279 for PS1-Syt1 interaction.
These findings were further validated by a complemen-
tary approach: immobilized metal affinity chromatography
(IMAC), designed for selective isolation of the His-tagged
proteins. PC12 cells were transiently transfected with His-
tagged wt or del265-279 mutant PS1, stimulated for 15
min with 50 mM KCl, and His-PS1 and endogenous Syt1
complexes were analyzed. We found that deletion of the
amino acids 265–279 within the PS1 sequence signifi-
cantly inhibits the PS1-Syt1 binding (Fig. 1c).
Of note, the PS1-Syt1 interaction is not dependent on the
PS1 endoproteolysis, as demonstrated by successful pull-
down of His-V5-tagged Syt1-PS1 wt as well as His-V5-
Syt1-PS1Δe9, lacking the endoproteolysis site, complexes
from PS double knock-out mouse embryonic fibroblasts
(PS DKO MEF) stably expressing respective PS1 variants
and transiently transfected with His-V5-Syt1 (Fig. 1d).
Based on these data, we designed a peptide correspond-
ing to the N-terminus of the PS1 loop domain (PS1-LNT)
to inhibit the PS1-Syt1 binding. The fragment was fused
with positively charged TAT HIV1 epitope to enable cell
permeability. In addition, for the initial experiments
aiming to monitor the peptide intracellular delivery, PS1-
LNT was conjugated with the fluorescein isothiocyanate
(FITC) (Fig. 2a).
As shown in Fig. 2, PS1-LNT-FITC at 5 μM can effi-
ciently permeate the cells within 2-h incubation (Fig. 2b)
without causing any toxicity (Fig. 2c). We also determined
that PS1-LNT does not alter PS1 endoproteolysis, as dem-
onstrated by the lack of significant changes in PS1 NTF
and PS1 CTF generation (Fig. 2d).
Next, to assess if the PS1-LNT can inhibit the target
interaction, we monitored proximity between endogenous
PS1 and Syt1 in intact primary neurons. For this, the cells
were pre-treated for 2 h with PS1-LNT or scramble peptide
as a control, stimulated for 15 min with 50 mM KCl or
H2O vehicle, immunostained with anti-PS1 NT and anti-
Syt1 antibodies, and relative proximity between the fluores-
cently labeled proteins was determined by FLIM. PS1-LNT
did not have any noticeable effect on the PS1-Syt1 inter-
action in the absence of KCl stimulation, due to relatively
low intracellular calcium concentration and minimal spon-
taneous activity of the in vitro cultured primary neurons
[41]. Thus, observed calcium-dependent PS1-Syt1 binding
is relatively scarce at the basal condition, as visualized by
the occasional red pixels on the pseudo-colored FLIM
images (Fig. 3a). As expected, KCl-mediated synchronous
calcium influx increased the relative FRET efficiency (PS1-
Syt1 proximity) by 29.53 ± 5.15%, p < 0.0001 in scramble
peptide pre-treated cells, similarly to that in non-pre-
treated neurons [12] (Fig. 3a and Additional file 1).
However, KCl failed to increase the EFRET in the PS1-LNT
pre-treated neurons (Fig. 3a and Additional file 1). These
data demonstrate that the effect of the PS1-LNT peptide is
the most pronounced in the KCl(+) condition, when it
reduces the efficiency of the PS1-Syt1 binding.
The ability of the PS1-LNT peptide to impede calcium-
dependent PS1-Syt1 interaction was further confirmed
using a complementary approach: IMAC in vitro PS1-Syt1
binding assay. His-V5-Syt1, extracted from the PS DKO
MEF cells transiently transfected with His-V5-Syt1, was
immobilized on the beads, and the beads were incubated
with mouse brain lysates, supplemented with 2 mM Ca2+,
in the presence of scramble or PS1-LNT peptide. Binding
of the endogenous PS1 to the immobilized His-V5-Syt1
was observed only in the presence of scramble peptide,
and was blocked by the presence of PS1-LNT (Fig. 3b).
Together, these data confirm the ability of PS1-LNT
peptide to inhibit calcium-triggered PS1-Syt1 interaction
in primary neurons.
PS1-Syt1 interaction modulates PS1 conformation and Aβ
secretion
We have previously demonstrated that PS1/γ-secretase
exists in a dynamic equilibrium of the distinct conform-
ational states, so called “closed” and “open”, as determined
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by varied distances between the fluorescently labeled PS1
N-terminus and PS1-C-terminus/loop domains. The con-
formation of PS1 affects the position of the γ-secretase
cleavage site on amyloid precursor protein (APP), and
hence impacts generation of the different amyloid β (Aβ)
species. Close PS1 domain arrangement, “closed”
Fig. 1 Determination of Syt1-interacting region within PS1 sequence. a Schematic presents the PS1-Syt1 complex and the 15-amino acid
deletion within the PS1 L6-7 sequence (del265-279). b Deletion within the L6-7 domain of PS1 inhibits PS1-Syt1 interaction. PC12 cells
transfected with FLAG-tagged wild type (wt) or del265-279 PS1 were immunostained with anti-FLAG and anti-Syt1 antibodies, followed by
fluorescently conjugated secondary antibodies, and analyzed by FLIM. The graph shows normalized FRET efficiency between fluorescently
labeled endogenous Syt1 and overexpressed PS1 in PC12 cells stimulated for 15 min with 50 mM KCl. The data are presented as mean ± SEM, n = 38
for PS1 wt, and n = 33 for PS1 del265-279, n = total number of cells analyzed in 3 independent experiments. Statistical significance was determined
using two-tailed unpaired Student’s t-test, ***p < 0.001. The fluorescence lifetimes and corresponding FRET efficiency values are specified in the
Additional file 1. c Syt1 co-purifies more efficiently with His-PS1 wt than with His-PS1 del265-279. Overexpressed His-tagged PS1 and endogenous Syt1
complexes extracted from PC12 cells following 15-min 50 mM KCl application were purified using immobilized metal affinity chromatography (IMAC)
and analyzed by western blotting; unspecific bands are marked with blue asterisks. PS double knock-out (PS DKO) mouse embryonic fibroblasts (MEF)
cells were used as a negative control. The adjacent graph presents quantification of the Syt1 levels co-purified with PS1. The data are presented as
mean ± SEM, n = 3; two-tailed unpaired Student’s t-test, ***p < 0.001. d PS1 with the deleted exon 9 (PS1Δe9) interacts with Syt1. PS DKO and PS DKO
cells stably expressing PS1 wt or PS1Δe9 were transiently transfected with His-V5-Syt1 and incubated for 15 min with 5 μM A23187 calcium ionophore.
Anti-His antibody or normal mouse IgG as a control were used for the immunoprecipitation, and anti-V5 and anti-PS1 CT antibodies were applied for
the immunodetection. The experiment was performed three times
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conformation, correlates with the increased Aβ42/40
ratio [12, 15, 21, 22].
To determine the role of the PS1-Syt1 interaction in
the modulation of PS1 conformation and Aβ production,
PS1 conformation was assayed in non-stimulated and
KCl-stimulated neurons, pre-treated with PS1-LNT or
scramble peptide, using antibody-based FLIM. The 15-min
KCl application triggered an increase in the FRET
efficiency, indicative of the shorter distance between the
fluorophores labeling PS1 NT and loop domains, in both
scramble and PS1-LNT pre-treated neurons, consistent
with the previous data for non-pre-treated cells [12].
Fig. 2 Design of the cell-permeable peptide and its application in primary neurons. a Schematic representation of the PS1-Syt1 complex.
The PS1 fragment used for the design of the cell-permeable peptide to inhibit the PS1-Syt1 interaction is indicated in red. The adjacent
image presents the fusion of the HIV1 TAT domain with the respective PS1 fragment. For initial experiments the peptide was conjugated
with fluorescein (FITC) to visualize intracellular delivery. Scramble peptide was used as a control. b Representative images demonstrate
successful delivery of 5 μM TAT-FITC and TAT-PS1-LNT-FITC (green) peptides to the primary neurons after two-hour incubation. The cells
were counterstained with phalloidin (red) and DAPI (blue) to visualize the actin cytoskeleton and the nuclei, respectively; scale bar 10 μm;
the magnified inserts demonstrate efficient entry of the FITC-labeled peptides into neuronal cell bodies and processes. c Analysis of the cytotoxicity of
the scramble and PS1-LNT peptides in neurons after two-hour incubation at the respective concentrations. The % cytotoxicity was determined using
lactase dehydrogenase (LDH) activity assay. The data are normalized to the 1% TX-100 condition, considered to cause 100% toxicity. There is negligible
toxicity of scramble and PS1-LNT peptides used at 2 μM and 5 μM final concentrations. The data are presented as mean ± SEM, n = 37 for 5 μM, n = 13
for 10 μM and n = 7 for the remaining conditions. Statistical significance was determined using two-tailed unpaired Student’s t-test, ***p < 0.001.
d Representative western blot shows efficient endoproteolysis of the full length PS1 (PS1-FL) to yield PS1-NTF and PS1-CTF in control and PS1-LNT
pre-treated neurons. The graph presents quantification of the optical density of the respective bands. The ratio between PS1-CTF or PS1-NTF and
PS1-FL was used to estimate endoproteolysis efficiency. The data are presented as mean ± SEM, n = 7. Statistical significance was determined using
two-tailed unpaired Student’s t-test, ns p > 0.05
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Interestingly, this increase was significantly higher in the
PS1-LNT pre-treated neurons, where binding to the Syt1
was blocked, compared to the scramble/control cells
(Fig. 4a and Additional file 1). This suggests that Syt1 via
binding to PS1 lessens the strong, “pathogenic” closure of
the PS1 conformation caused by high calcium.
To test whether inhibition of the PS1-Syt1 interaction
would affect Aβ production/secretion, the Aβ42 and
Aβ40 levels in the conditioned medium of the PS1-LNT
and control pre-treated neurons were measured. We
found that inhibition of the interaction between PS1 and
Syt1 results in a significant increase in the Aβ42/40 ra-
tio, although individual levels of the Aβ40 and Aβ42
were reduced (Fig. 4b).
The reduced Aβ levels in the conditioned medium could
be a consequence of the changed APP expression and/or
processing, or impaired Aβ secretion. To distinguish be-
tween these possibilities, we evaluated the levels of APP
full length (APP-FL) and APP C-terminal fragments
(APP-CTFs) in KCl-stimulated scramble and PS1-LNT
pre-treated neurons. No accumulation of the APP-CTFs
was observed upon the inhibition of the PS1-Syt1 binding,
suggestive of the lack of alterations in the overall
PS1/γ-secretase activity (Additional file 2).
To explore if the observed decrease in the Aβ amount
in the conditioned medium is indeed a consequence of
the impaired Aβ secretion, we measured intracellular
Aβ42 and Aβ40 levels in the control or PS1-LNT pre-
treated, KCl-stimulated neurons (Fig. 4c). An increased
amount of the intracellular Aβ42 and Aβ40 was detected
in the cells pre-treated with PS1-LNT compared to the
control, suggesting that inhibition of the PS1-Syt1
Fig. 3 Inhibition of calcium-induced PS1-Syt1 interactions in primary neurons using PS1-LNT peptide. a The PS1-Syt1 proximity in neurons pre-treated
with PS1-LNT or scramble peptide at the basal (KCl(-)) conditions or after 15-min depolarization with 50 mM KCl was determined by FLIM. The neurons
were immunostained with anti-PS1 N-terminus (NT) and anti-Syt1 antibodies, followed by fluorescently conjugated secondary antibodies. The change
in FRET efficiency was used to estimate relative change in the proximity between PS1 and Syt1. The pseudo-colored image presents the lifetime of the
donor fluorophore in picoseconds. The orange-red pixels indicate shorter lifetimes reflecting closer proximity between the fluorescently labeled PS1
and Syt1; scale bar 10 μm. The graph shows normalized FRET efficiency between PS1 and Syt1. Note, PS1-LNT-mediated inhibition of the
calcium-induced PS1-Syt1 interaction in neurons. The data are presented as mean ± SEM, n = 64 for scramble KCl (-), n = 70 for PS1-LNT
KCl (-), n = 68 for scramble KCl (+) and n = 70 for PS1-LNT KCl (+), n = total number of neurons analyzed in 3 independent experiments.
Statistical significance was determined using two-tailed unpaired Student’s t-test, ***p < 0.001. The fluorescence lifetimes and corresponding FRET
efficiency values are shown in the Additional file 1. b In vitro IMAC analysis demonstrates successful inhibition of the PS1 binding to Syt1 by the
PS1-LNT peptide. His-V5-Syt1 expressed in PS DKO cells was purified and immobilized on the beads using immobilized metal affinity chromatography,
IMAC. The beads were incubated with mouse brain lysate in the presence of scramble or PS1-LNT peptide. The blue arrow indicates
bands corresponding to the Syt1 immobilized on the beads. The red arrow shows the band corresponding to PS1 CTF bound to the
immobilized Syt1 in the presence of scramble peptide only. Gapdh immunobloting was used as control. n = 3 independent experiments
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binding may result in aberrant exocytosis. These results
were further supported by double-immunostaining of
neurons with the anti-β-amyloid antibody 4G8, recog-
nizing both Aβ and APP, and anti-microtubule associ-
ated protein 2 (MAP2) antibody as an internal control.
Since we did not see difference in the APP-FL and APP-
CTFs between the scramble and PS1-LNT pre-treated
cells, increased 4G8 fluorescence intensity in PS1-LNT
pre-treated cells (Additional file 3) suggests accumula-
tion of the intracellular Aβ.
Next, we determined whether PS1-LNT impaired exocy-
tosis is specific for Aβ or represents more general
phenomena. Multiple proteins are released from neurons in
an activity-dependent exocytosis controlled by synaptic pro-
teins [42–44]. Thus, we used an accurate and ultrasensitive
NanoOrange assay to monitor changes in the total protein
concentration in the conditioned medium of neurons pre-
treated for 2 h with PS1-LNT or scramble peptide, and
stimulated with 50 mM KCl for 15 min. Indeed, the amount
of total protein detected in the conditioned medium of
PS1-LNT pre-treated neurons was significantly reduced,
compared to that of scramble pre-treated cells (Fig. 5a).
This further supports overall impairment of exocytosis/
secretion after the inhibition of the Syt1-PS1 binding.
Fig. 4 Activity-driven PS1-Syt1 interaction stabilizes open PS1 conformation and modulates Aβ production/secretion. a The conformation of
endogenous PS1 in primary neurons pre-treated with PS1-LNT or scramble peptide at basal (KCl(-)) and high calcium (upon 15-min 50 mM KCl
stimulation) conditions was determined by FLIM assay, monitoring proximity between PS1 N-terminus and PS1 loop domain. Cells were
immunostained with anti-PS1 NT and anti-PS1 loop antibodies, followed by fluorescently conjugated secondary antibodies. The pseudo-colored
images present the donor fluorophore lifetime in picoseconds. The orange-red pixels indicate PS1 in “closed” conformation; scale bar 10 μm. The
adjacent graph presents normalized FRET efficiency between PS1-NT and PS1 cytosolic loop. The KCl stimulation shifts PS1 to “closed” conformation in
both scramble and PS1-LNT pre-treated neurons but the shift is greater in the PS1-LNT conditions. The data are presented as mean ± SEM, n = 64 for
scramble (KCl(-)), n = 57 for PS1-LNT (KCl(-)), n = 59 for scramble (KCl(+)) and n = 65 for PS1-LNT (KCl(+)), n = number of neurons analyzed
in 3 independent experiments. Statistical significance was determined using two-tailed unpaired Student’s t-test, **p < 0.01. The fluorescence lifetimes
and corresponding FRET efficiency values are shown in the Additional file 1. b The graph presents relative Aβ40, Aβ42 levels and Aβ42/40 ratio in
conditioned medium collected from the neurons pre-treated with PS1-LNT and depolarized with KCl to induce calcium influx. The values, determined
by ELISA, were normalized to the scramble treated cells. The data are presented as mean ± SEM, n = 19-26. Statistical significance was determined using
two-tailed unpaired Student’s t-test, *p < 0.05, **p < 0.01. c The graph presents relative Aβ40 and Aβ42 levels in cell lysates prepared from the neurons
used in (b). The values were normalized to the scramble treated cells. The data are presented as mean ± SEM, n = 7-12. Statistical significance was
determined using two-tailed unpaired Student’s t-test, *p < 0.05, **p < 0.01
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PS1-Syt1 interaction stimulates exocytosis and
neurotransmitter release in primary neurons
Syt1 is primarily expressed at the synapse and calcium in-
flux has been shown to predominantly trigger PS1-Syt1
interaction at the synaptic loci [12]. This rises a possibility
that PS1-Syt1 binding may modulate synaptic vesicle
exocytosis and neurotransmitter release. Therefore, to
examine whether the PS1-Syt1 interaction indeed modu-
lates synaptic exocytosis we monitored the level of
secreted glutamate over the 150-min time course in the
conditioned medium of KCl-stimulated neurons pre-
treated for 2 h with 5 μM of either PS1-LNT or scramble
peptides. A blocker of the excitatory amino acid trans-
porters 1 and 2 (EAAT1, EAAT2), DL-threo-beta-benzy-
loxyaspartate (DL-TBOA), was used to inhibit glutamate
re-uptake. The inhibition of the PS1-Syt1 binding by PS1-
LNT resulted in a significant reduction of the glutamate
level in the conditioned medium (Fig. 5b), suggesting
importance of the PS1-Syt1 interaction for glutamate
secretion/exocytosis. Overnight pre-treatment of the neu-
rons with tetanus toxin (TeTx), a commonly used potent
inhibitor of the exocytosis [45], markedly diminished
glutamate release, and served as an assay control. Import-
antly, the described reductions in glutamate release in the
Fig. 5 PS1-Syt1 interaction modulates exocytosis/neurotransmitter release. a The graph presents the quantification of the total protein amount in the
conditioned medium collected from neurons plated at 1.5x106 cells/well, pre-treated for 2 h with scramble and PS1-LNT peptides, and stimulated for
15 min with 50 mM KCl. The protein secreted by the PS1-LNT pre-treated neurons is shown as a percent of the protein secreted by the scramble
peptide pre-treated cells; mean ± SEM, n = 12. Statistical significance was determined using two-tailed unpaired Student’s t-test, ***p < 0.001. b The
graph presents relative amounts of glutamate in the conditioned medium collected from neurons pre-treated for 2 h with PS1-LNT, scramble
peptide or exocytosis inhibitor, tetanus toxin (TeTx), and depolarized using 50 mM KCl in the presence of the DL-TBOA, an inhibitor of the glutamate
transporters EAAT1 and EAAT2. The data are presented as mean ± SEM, n = 31 for scramble and PS1-LNT, n = 6 for TeTx. Statistical significance
was determined using two-way ANOVA followed by Bonferroni’s post-test, **p < 0.01, *** < 0.001. c The graph presents relative level of lactate
dehydrogenase activity, indicative of the potential cytotoxicity of the applied treatment, in primary neurons pre-treated with PS1-LNT or scramble
peptide for 2 h and depolarized using 50 mM KCl in the presence of the DL-TBOA for the duration of the assay. The data are presented as mean ± SEM,
n = 7. Statistical significance was determined using two-way ANOVA followed by Bonferroni’s post-test. No significant toxicity of the applied
treatments was observed. d, The pseudocolor-coded images present synaptophluorin (SypHy) fluorescence at the synaptic puncta in neurons
pre-treated for 2 h with PS1-LNT or scramble peptide. The red spots indicate high fluorescence intensity corresponding to the high level of
exocytosis observed immediately after the 50 mM KCl stimulation; scale bar 5 μm. The adjacent bar graph demonstrates the quantification of the
increase in SypHy fluorescence at the synaptic ROIs in response to the depolarizing stimulus in the scramble and PS1-LNT pre-treated neurons.
The data are presented as mean ± SEM, n = 263 for scramble and n = 255 for PS1-LNT, n = number of synaptic puncta analyzed in 4 independent
experiments. Statistical significance was determined using Mann-Whitney’s U-test, ***p < 0.01
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PS1-LNT and TeTx pre-treated neurons were not due to
increased cytotoxicity (Fig. 5c).
The role of PS1-Syt1 interactions in synaptic vesicle
exocytosis was further assessed using an alternative
approach, monitoring fluorescence intensity of the pH-
sensitive reporter of the synaptic vesicle exocytosis,
synaptophluorin (SypHy) [33]. The SypHy was expressed
in 13 DIV neurons, and changes in its fluorescence
intensity pre- and post-KCl stimulation were monitored
in real time in live cells pre-incubated with PS1-LNT or
scramble peptide. No marked differences in the SypHy
expression were observed between PS1-LNT and scram-
ble peptide treated neurons at the baseline conditions
(Fig. 5d, KCl(-)). As expected, the fluorescence intensity
increased immediately after the KCl application, indica-
tive of synaptic vesicle exocytosis, but the increase was
less prominent in PS1-LNT than in scramble treated
neurons (Fig. 5d, KCl(+)).
Collectively, the decreased level of Aβ and glutamate in
the conditioned medium, and reduced rise in the SypHy
fluorescence in KCl-stimulated neurons after inhibition of
the PS1-Syt1 interactions strongly suggest that the PS1-Syt1
binding may help upkeep exocytosis in primary neurons.
PS1-Syt1 binding influences trafficking of synaptic
vesicles
To further address the role of PS1-Syt1 interaction in syn-
aptic physiology, the mobility of synaptic vesicles along
the processes was investigated using fluorescence recovery
after photobleaching (FRAP) of the eGFP-synaptophysin
(eGFP-Syp). eGFP-Syp has been previously reported to be
predominantly expressed in axons and to co-localize with
the other synaptic vesicle markers [46, 47]. The neurons
expressing eGFP-Syp were pre-treated with 5 μM scram-
ble or PS1-LNT peptides for 2 h and stimulated for 15
min with 50 mM KCl to promote PS1-Syt1 interaction.
The inhibition of the PS1-Syt1 binding by PS1-LNT led to
decreased recovery rate of the eGFP-Syp fluorescence
(Fig. 6a,b), suggestive of compromised synaptic vesicle
movement in PS1-LNT vs. scramble peptide pre-treated
cells. Of note, FRAP of the eGFP-tubulin, which served as
a negative control, was not altered by the PS1-LNT pre-
treatment (Fig. 6c,d).
Inhibition of PS1-Syt1 interaction leads to alterations in
the synaptic vesicle morphology and distribution
To determine if PS1-LNT interference with the PS1-Syt1
binding may lead to ultrastructural alterations at the
synapse, we performed electron microscopy (EM) ana-
lysis of the synaptic vesicle size, density and distance
from the active zone in primary neurons pre-treated for
2 h with scramble or PS1-LNT peptide, and stimulated
for 15 min with 50 mM KCl (Fig. 7). A population of
significantly larger synaptic vesicles and reduced overall
synaptic vesicle density were detected in synaptic termi-
nals of the PS1-LNT pre-treated neurons compared to
the control. Moreover, an increase in the distance of the
synaptic vesicle to the active zone was observed upon
the inhibition of the PS1-Syt1 binding.
Inhibition of the PS1-Syt1 interaction leads to the loss of
dendritic spines
In order to investigate the pathophysiological relevance of
the observed abnormalities in the exocytosis, synaptic
vesicle trafficking and ultrastructural impairments, we
analyzed the number and the morphology of the dendritic
spines in KCl-stimulated scramble or PS1-LNT peptide
pre-treated neurons. The inhibition of the PS1-Syt1 inter-
action resulted in the reduction of the total number of
dendritic spines (Fig. 8). In addition, when the dendritic
spines were classified according to their shape into
mushroom-shaped, stubby or thin, the decrease in the
fraction of mushroom spines was apparent in the
PS1-LNT pre-treated neurons. This further reaffirms the
importance of the PS1-Syt1 binding for the physiology of
the synapse.
Syt1 level and PS1-Syt1 proximity are decreased in
Alzheimer’s disease brains
Synaptic defects, impaired exocytosis, and pathogenic
change in the PS1 conformation were reported to occur
in AD [38, 48–51]. Since our data show that these were
affected by the inhibition of the PS1-Syt1 interaction, we
analyzed Syt1 protein expression and the relative prox-
imity between PS1 and Syt1 in medial temporal cortex
from sporadic AD (sAD) cases with neuropathologically
confirmed Braak stage V-VI, and in age- and post mortem
interval (PMI)-matched control subjects. The number and
fluorescence intensity of the Syt1-positive puncta were
significantly decreased in sAD brains (Fig. 9a).
To determine if the proximity between the remaining
Syt1 and PS1 is also altered in sAD, we employed an
antibody-based FLIM assay. FLIM approach determines
the fluorophore lifetime, which is an intrinsic biophysical
property of a fluorophore, and hence does not depend on
the absolute amounts of the donor and the acceptor in the
sample [36, 52, 53]. Therefore, despite significant reduc-
tion in the absolute levels of synaptic proteins in AD
brain, FLIM is uniquely suited to report the relative
distance between the remaining Syt1 and PS1. Longer
lifetimes of the donor fluorophore, indicative of the lower
FRET efficiency, stemming from reduced proximity be-
tween the fluorescently labeled PS1 and Syt1, were re-
corded in sAD compared to control cases (Fig. 9b and
Additional file 1). This indicates that in addition to
decreased Syt1 level, the interaction between Syt1 and
PS1/γ-secretase in sAD brains is also significantly reduced.
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Syt1 overexpression in vivo in mouse brain promotes
protective “open” PS1 conformation
To investigate whether overexpression of Syt1 in vivo in
mouse hippocampi would promote the PS1-Syt1 inter-
action, and thus support the protective “open” PS1
conformation, we employed adeno-associated virus
(AAV2/8)-mediated delivery of the Syt1-V5 or empty
vector control plasmids into the hippocampi of wild type
C57BL/6 mice. To minimize variability between the ani-
mals Syt1-V5 was expressed in one hemisphere and an
Fig. 6 PS1-Syt1 interaction modulates synaptic vesicle trafficking. a Fluorescent images show distribution of the eGFP-synaptophysin (eGFP-Syp)
in primary neurons pre-treated for 2 h with scramble and PS1-LNT peptides. Note increased fluorescence intensity in synaptic puncta along the
processes. The arrows point to the example region of interests (ROIs) used for the photobleaching experiments; scale bar 15 μm. b Fluorescence
recovery after photobleaching (FRAP) experiments demonstrate impaired motion of synaptic vesicle proteins in the PS1-LNT pre-treated neurons.
The fluorescent images present 5 μm-diameter ROIs recorded in eGFP-Syp expressing neurons pre-treated for 2 h with scramble or PS1-LNT
peptides, and stimulated for with 50 mM KCl. Three ROIs are analyzed for each condition: pre-bleach, immediately after bleach and 10 s after
bleach. The adjacent bar graph demonstrates the quantification of the eGFP-Syp fluorescence recovered within 10 s post-bleach. The data are
presented as mean + SEM, n = 36. Statistical significance was determined using unpaired Student’s t-test, ***p < 0.001. c Fluorescent images
present distribution of the eGFP-tubulin (eGFP-Tub) in primary neurons pre-treated with scramble and PS1-LNT peptides. The arrows point to
the ROIs used for the photobleaching experiments; scale bar 15 μm. d Control FRAP experiments demonstrate no alterations in eGFP-tubulin
fluorescence recovery after photobleaching in neurons pre-treated for 2 h with PS1-LNT or scramble peptides, and stimulated with 50 mM KCl for
15 min. The fluorescent images present 5 μm-diameter ROIs recorded in eGFP-Tub expressing neurons pre-treated with scramble or PS1-LNT
peptides. The data are presented as mean + SEM, n = 19. Statistical significance was determined using unpaired Student’s t-test
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empty vector was delivered to the contralateral side
(Fig. 10a). One month post-injection the brains were dis-
sected and the Syt1-V5 expression in the targeted hemi-
sphere was confirmed by immunostaining with anti-V5
antibody (Fig. 10b). We found that increased Syt1 ex-
pression promoted the interaction between PS1 and
Syt1, as determined by antibody-based FLIM assay
(Fig. 10c and Additional file 1).
Next, we analyzed if increased Syt1 expression and its
interaction with PS1 would promote “open” PS1 conform-
ation in vivo. Significantly decreased FRET efficiency,
indicative of a longer distance between fluorescently labeled
PS1 N-terminus and large cytosolic loop domain, was
observed in the hemisphere injected with the AAV2/8-
Syt1-V5 compared to the contralateral control hemisphere
(Fig. 10d and Additional file 1). This reaffirms that Syt1
expression in vivo helps sustain protective “open” PS1 con-
formation and might be worth exploring therapeutically.
Discussion
By using targeted inhibition of the presenilin 1 (PS1)
and synaptotagmin 1 (Syt1) binding, without affecting
the proteins’ expression levels, we provide evidence of
the reciprocal relationship between PS1 and synaptic
vesicle protein Syt1, by showing that PS1 and Syt1
modulate each other’s functions. Furthermore, we found
that proximity between the Syt1 and PS1 is significantly
reduced in sporadic Alzheimer’s disease (sAD) brain,
indicating physiological relevance of the PS1-Syt1 inter-
action, and suggesting that disrupted interaction may
contribute to the synaptic pathology that starts early in
the disease.
Fig. 7 Inhibition of PS1-Syt1 binding leads to the alterations in synaptic vesicle morphology and distribution. Representative electron micrographs
show synaptic vesicles within the synapses of the primary neurons pre-treated for 2 h with scramble or PS1-LNT peptides, and stimulated for 15
min with 50 mM KCl. Enlarged synaptic vesicles in the PS1-LNT treated synapses are shown by red asterisks. Scale bar 100 nm. The graphs show
the quantification of: a synaptic vesicle size; b density; and c distance from the active zone. The data are normalized to scramble-treated cells and
presented as mean ± SEM, n = 100, n = total number of synapses analyzed in three independent experiments. Graph (d) presents the frequency
distribution of the synaptic vesicles within individual synapses as a function of the distance from the active zone. Statistical significance was determined
using two-tailed unpaired Student’s t-test (a, b, c) or two-way ANOVA followed by Bonferroni’s post-test (d), *p < 0.05, **p< 0.01, ***p< 0.001
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A link between abnormal neuronal/synaptic activity and
Aβ accumulation has been reported [54–56] although the
precise molecular mechanisms regulating synaptic Aβ gen-
eration and release remain elusive. We found that blocking
KCl-triggered PS1-Syt1 interaction affected both the type
of Aβ species generated and their release, without affecting
overall γ-secretase activity or APP processing. First, tar-
geted, peptide-based inhibition of the PS1-Syt1 binding ex-
acerbated KCl-induced shift of PS1 towards the pathogenic
“closed” state, and caused concurrent increase in the
Aβ42/40 ratio. This suggests that Syt1 may serve as a pro-
tective factor stabilizing “open” PS1/γ-secretase conform-
ation at the synapse at high calcium conditions. Second,
we found that inhibition of the interaction between PS1
and Syt1 resulted in the reduced overall protein secretion
and neurotransmitter release, and increased accumulation
of the intracellular Aβ, indicating that PS1 may be involved
in Syt1-mediated vesicle trafficking and exocytosis in
primary neurons.
The potential role of PS1 at the synapse beyond γ-
secretase activity remains poorly understood. The com-
promised neurotransmission has been observed in con-
ditional pre- but not post-synaptic PS double knock-out
neurons (PS cDKO), proposing a role of PS1 in the
modulation of neurotransmitter release [23]. Since PS1
interacts with the ryanodine receptor (RyR) [57], and PS
cDKO mice present reduced RyR level [58], the impaired
neurotransmission in PS cDKO neurons has been attrib-
uted to the aberrant calcium release through RyR [23].
On the other hand, γ-secrease activity-dependent PS1
involvement in regulation of the spontaneous neuro-
transmitter release was also shown in PS1 knock-out
neurons [24]. However, given the pleiotropic effect of
protein knock-out and considering multiple functions of
presenilins, as shown by the global PS1-dependent tran-
scriptome changes [59], PS1 knock-out approach does
not provide evidence of the direct involvement of PS1 in
synaptic vesicle exocytosis/neurotransmission.
Fig. 8 Inhibition of PS1-Syt1 interaction alters the number and the morphology of dendritic spines. a Representative images of the dendritic spines in
GFP overexpressing neurons, pre-treated for 2 h with scramble or PS1-LNT peptides, and stimulated for 15 min with 50 mM KCl. Scale bar 5 μm. The
adjacent bar graph shows the quantification of the dendritic spine density. The values are normalized to the scramble treated cells. The data are
presented as mean ± SEM, n = 30, n = number of neurites analyzed per condition in 8 independent experiments. Statistical significance was determined
using two-tailed unpaired Student’s t-test, ***p < 0.01. b The bar graph presents quantitative analysis of the relative contribution of the mushroom,
stubby and thin dendritic spines to the total spine number in neurons shown in (a). The data are presented as mean ± SEM, n = 50 for scramble and
n = 43 for PS1-LNT, n = number of images acquired per condition in 8 independent experiments. Statistical significance was determined using
two-way ANOVA followed by a Bonferroni’s post-test, *p < 0.05
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Our discovery of the calcium-regulated PS1 interaction
with the synaptic vesicle release protein, Syt1, further
alluded to the possibility that PS1 may play an important
regulatory role at the synapse. Since Syt1 is directly in-
volved in calcium-triggered exocytosis that depends on its
precise, sequential interactions with the SNARE complex
proteins, allowing vesicle fusion to occur and exocytosis
to proceed [27–29, 60, 61], we hypothesized that PS1
binding to Syt1 may modulate this process. Consistent
with this idea, our findings demonstrate that targeted in-
hibition of the PS1 interaction with one of the members
of synaptic vesicle release machinery diminishes the activ-
ity driven exocytosis/glutamate release. Moreover, reduced
recovery rate of the eGFP-synaptophysin fluorescence
after photobleaching suggests compromised synaptic
vesicle trafficking along the neuronal processes when the
PS1-Syt1 interaction is impeded. These impairments may
manifest with an altered distribution of the vesicles at the
synapses. Indeed, electron microscopy analysis revealed
enlarged, less densely packed synaptic vesicles that are po-
sitioned farther from the active zone in KCl-stimulated
neurons after the inhibition of the PS1-Syt1 binding.
These data suggest that PS1-LNT interference with the
PS1-Syt1 interaction may lead to alterations in synaptic
vesicle morphology/distribution at the synapse and com-
promise exocytosis. It is plausible that PS1 via the direct
interaction with Syt1 regulates its structural flexibility
and/or presentation of specific motifs on Syt1 necessary
for the interaction with other synaptic partners crucial for
synaptic vesicle exocytosis [62–65]. On the other hand,
accumulation of the enlarged vesicles might indicate that
the PS1-Syt1 binding regulates the Syt1-dependent mech-
anisms controlling synaptic vesicle size [66]. Of note,
analogous structural abnormalities in the synaptic vesicles
have been observed in Syt1 knock-out synapses [67, 68],
but not in the Syt1 calcium-binding motif mutants [67],
indicating that this is not a Syt1 calcium-binding defect.
The impairments in the exocytosis and neurotransmitter
release at the pre-synapse due to the inhibition of the
PS1-Syt1 interaction lead to the concomitant reduction in
the number of dendritic spines, and mushroom spines in
particular. This finding is consistent with the previous
observations of decreased spine density in vivo following
the expression of potent exocytosis inhibitors [69] and in
AD models, as reviewed in [70, 71]. Together, with our
findings of the detrimental effect of PS1-LNT blocking
peptide treatment on PS1 conformation, Aβ42/40 ratio
and intracellular Aβ accumulation, this further supports
the beneficial role of the PS1-Syt1 interaction for synaptic
wellbeing.
The described pathophysiological changes were detected
in vitro upon profound but relatively short-lasting inhibition
of the PS1-Syt1 binding. It is plausible that chronic, lasting
over decades inhibition of the PS1-Syt1 interaction, even if
Fig. 9 Reduced Syt1 level and PS1-Syt1 interactions in human sporadic
AD brains. a Representative images of the Syt1 immunoreactivity in
the medial temporal cortex of control and Braak V-VI stage sporadic
AD brains; scale bar 10 μm. The inserts present magnified areas from
the images and demonstrate the individual synaptic puncta (arrows).
The bar graph presents quantification of the number and intensity of
the Syt1-positive puncta in control vs. sAD patients. The data are
presented as mean ± SEM, n = 4, 4–5 fields analyzed for each case.
Statistical significance was determined using two-tailed unpaired
Student’s t-test. *p < 0.05, **p < 0.01. There is a significant reduction
in the Syt1 immunofluorescence in sAD brains. b FLIM analysis of
PS1-Syt1 interactions in medial temporal cortex of control vs. sAD
presents reduced PS1-Syt1 binding in sAD. The tissue was
immunostained with anti-PS1 NT (APS11) and anti-Syt1 antibodies,
and relative proximity between the fluorescently labeled proteins
was determined by FLIM. There is significant reduction in the FRET
efficiency between PS1 and Syt1, indicative of a greater distance
between the molecules, in sAD brains. The data are presented as
mean ± SEM, n = 4; 20–25 neurons analyzed for each case. Statistical
significance was determined using Mann-Whitney’s U-test. *p < 0.05.
The fluorescence lifetimes and corresponding FRET efficiency values
are shown in the Additional file 1
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more subtle, would lead to the neuronal circuitry dysfunc-
tion, and ultimately to AD. In accordance, several studies
have reported changes in the synaptic physiology and exo-
cytosis, such as alterations in RCAN1-mediated modulation
of exocytosis in AD [49, 51] or exocytosis impairments in
the cells from APP/PS1 mouse model of AD [50].
Synaptic dysfunction/loss is one of the major neuro-
pathological feature of the disease, and the strongest
correlate of the disease progression [1–3, 7, 48, 72]. The
described protective Syt1 function might be compromised
in AD brains, since, in agreement with other reports, we
found reduced levels of Syt1 in sAD brains (this study and
[7, 73]). Intriguingly, reduced Syt1 level in the brain is
followed by its concomitant decrease in the cerebrospinal
fluid and plasma neuronal-derived exosomes, raising the
prospect for Syt1 being used as a potential biomarker for
synaptic AD pathology [74, 75].
Furthermore, by applying fluorescence lifetime im-
aging microscopy, we found that the proximity between
the remaining Syt1 and PS1 is also reduced in the
disease. Of note, we have observed that the PS1-Syt1
interaction in mouse brain increases during normal
aging (unpublished data). Therefore, it is possible that
the PS1-Syt1 proximity is also higher in normal aged hu-
man brain (perhaps as a compensatory mechanism) but
not in the sporadic AD brain. There is an array of fac-
tors that could potentially affect the baseline PS1-Syt1
interaction in aged brain. Despite the lack of PS1 muta-
tions, the wild type PS1 in sAD brain presents structural
alteration, i.e. pathogenic “close” conformation that is
linked to elevated Aβ42/40 ratio [38, 76, 77]. Therefore, it
is possible that conformational changes in PS1 might result
in reduced binding to Syt1. It is also possible that reduction
in the PS1-Syt1 binding can occur early, before the onset of
symptoms, since ~30% decrease in the PS1-Syt1 interaction
is observed in 9 month old Tg2576 AD mice without syn-
aptic loss and before the appearance of amyloid plaque
pathology (unpublished data). Together with other factors,
the impaired PS1-Syt1 binding may weaken the synapse via
local increase in the Aβ42/40 ratio and deficits in the
Fig. 10 Syt1 overexpression in vivo increases PS1-Syt1 interactions and promotes open PS1 conformation in mouse brain. a Schematic
representation of the experimental design. Bilateral injection of AAV2/8-hSyn1. Syt1-V5 or empty plasmid to the contralateral hemisphere
was performed. One month after the injections the brains were dissected and subjected to immunofluorescence analysis. b The fluorescent images
demonstrate successful expression of Syt1-V5 in mouse brain one month after the AAV2/8-hSyn1. Syt1-V5 injection. The tissue was immunostained
with anti-V5 antibody and corresponding Cy3-conjugated secondary antibody. c, d The bar graphs present FLIM assays of the PS1-Syt1 interactions
and PS1 conformation in mouse hippocampi injected with AAV2/8-hSyn1. Syt1-V5 or empty vector as a control. The tissue was immunostained with
anti-PS1 NT and anti-Syt1 for the PS1-Syt1 interaction assay, or anti-PS1 NT and anti-PS1 loop antibodies for the PS1 conformation assay, followed by
respective fluorescently labeled secondary antibodies. There is a significant increase in the PS1-Syt1 binding and a shift towards protective “open”
conformation of PS1 in the hemispheres transduced with AAV2/8-hSyn1. Syt1-V5. The data are presented as mean ± SEM, n = 721-723 neurons for
PS1-Syt1 interaction and n = 573-586 for PS1 conformation were analyzed in 5 mice. Statistical significance was determined using Mann-Whitney’s
U-test, ***p < 0.001. The fluorescence lifetimes and corresponding FRET efficiency values are shown in the Additional file 1
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overall protein exocytosis/neurotransmitter release, contrib-
uting to the synaptic loss.
Finally, since reduced Syt1 level and diminished PS1-
Syt1 binding have a detrimental effect on PS1 conform-
ation, we reasoned that overexpression of Syt1 in vivo in
the brain might induce the protective “open” PS1 subdo-
main architecture. Indeed, we found that AAV-mediated
delivery of the Syt1 into mouse hippocampi promotes the
PS1-Syt1 binding, and impels the PS1 protective “open”
conformational state. These findings suggest a therapeutic
potential through fostering the PS1-Syt1 interaction for
AD treatment. It is possible that this strategy may consti-
tute a synapse-specific complementary approach to using
GSMs. GSMs are known to reduce the pathogenic Aβ42/
40 ratio [78–80], and a number of GSMs tested had
promoted “open” PS1 conformation in both neuronal and
non-neuronal cells [21, 22, 81].
Collectively, the data reveal novel role of PS1 and Syt1
at the synapse; present a reduction in the PS1-Syt1 inter-
actions as potential molecular contributor to AD patho-
genesis; and open avenues for novel synapse-specific
AD-targeting therapeutic interventions.
Conclusions
The study reveals novel role of presenilin 1 (PS1) and syn-
aptotagmin 1 (Syt1) at the synapse. It demonstrates that
PS1 and Syt1 can influence each other function via direct
interaction. Furthermore, it reports that the PS1-Syt1 bind-
ing is reduced in sporadic Alzheimer’s disease (sAD) brains,
which may contribute to the abnormal PS1/γ-secretase
conformation, increased amyloid β (Aβ) 42/40 ratio, and
impaired neurotransmitter release. The findings in this
study indicate that fostering PS1-Syt1 interaction might
serve as a novel synapse-specific therapeutic approach for
AD. In summary, the reported data point towards novel
mechanism regulating synaptic physiology and relative gen-
eration of the longer to shorter Aβ species, describe new
pathogenic mechanisms of AD, and propose novel thera-
peutic target for the disease.
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Additional file 1: Fluorescence lifetime and corresponding FRET
efficiency values recorded in the FLIM assays. The table summarizes the
mean ± SEM fluorescence lifetimes and corresponding, calculated FRET
efficiencies for the all presented FLIM analyses. (XLSX 14 kb)
Additional file 2: Inhibition of PS1-Syt1 interaction does not affect APP
expression and APP-CTF levels. The representative western blot demonstrates
levels of APP-FL, APP-CTFs and Gapdh, as a loading control, in the protein
lysates extracted from primary neurons pre-treated with scramble or PS1-LNT
peptides for 2 h and stimulated for 15 min with 50 mM KCl. The adjacent
graph shows the quantification of the APP-FL levels relative to Gapdh, and
APP processing rate as an APP-CTFs/APP-FL ratio. The values were normalized
to the scramble pre-treated cells. The data are presented as mean ± SEM,
n= 10-11. Statistical significance was determined using two-tailed unpaired
Student’s t-test, ns p> 0.05. (TIF 3734 kb)
Additional file 3: Inhibition of the PS1-Syt1 interaction leads to
intraneuronal Aβ accumulation. The representative images demonstrate
immunofluorescent staining of primary neurons pre-treated with scramble
or PS1-LNT peptides, and depolarized for 15 min with 50 mM KCl. Anti-MAP2
(red) and anti-β-amyloid 17–24, clone 4G8 (green) antibodies were used; scale
bar 10 μm. The adjacent graph presents the quantification of the fluorescent
intensity of Aβ/APP normalized to the MAP2 fluorescence. The values
were normalized to the scramble treated cells. The data are presented as
mean ± SEM, n = 105 for scramble and n = 96 for PS1-LNT, n = number of
neurons analyzed in 4 independent experiments. Statistical significance
was determined using two-tailed unpaired Student’s t-test, ***p < 0.001.
(TIF 5598 kb)
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